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BACKGROUND: Advanced biliary cancer is often treated with fluoropyrimidine-based chemotherapy. In this study, we evaluated the efficacy
and tolerability of a combination of S-1, an oral fluoropyrimidine prodrug, and oxaliplatin in patients with metastatic biliary cancer.
METHODS: Patients with histologically confirmed metastatic biliary cancer and no history of radiotherapy or chemotherapy were enrolled.
Oxaliplatin was administered intravenously (130mgm
 2), followed by 14-day administration of oral S-1 (40mgm
 2 twice daily) with a
subsequent 7-day rest period every 21 days. Pharmacokinetic analysis of S-1 was performed at cycle 1. Patients were genotyped for
CYP2A6 polymorphisms (*1, *4, *7, *9 or *10), and pharmacokinetic and clinical parameters compared according to the CYP2A6 genotype.
RESULTS: In total, 49 patients were evaluated, who received a median of four cycles. The overall response rate was 24.5%. Median
progression-free and overall survival was 3.7 and 8.7 months, respectively. The most common haematological grade 3 out of 4
toxicity was neutropenia (14%), while non-hematological grade 3 out of 4 toxicities included anorexia (14%), nausea (12%), asthenia (10%),
vomiting (10%), and diarrhoea (4%). Biotransformation of S-1 (AUC0 24h of 5-fluorouracil/AUC0 24h of tegafur) was 1.85-fold higher for
the *1/*1 group than for the other groups (90% confidence interval 1.37–2.49). Diarrhoea (P¼0.0740), neutropenia (P¼0.396), and
clinical efficacy (response rate, P¼0.583; PFS, P¼0.916) were not significantly associated with CYP2A6 genotype, despite differences in
5-FU exposure.
CONCLUSION: The combination of S-1 and oxaliplatin appears to be active and well tolerated in patients with metastatic biliary cancer,
and thus is feasible as a therapeutic modality. CYP2A6 genotypes are associated with differences in the biotransformation of S-1. However,
the impact of the CYP2A6 polymorphism on variations in clinical efficacy or toxicity requires further evaluation.
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Biliary tract cancer (BTC), including cancer of the gallbladder
and the intrahepatic and extrahepatic bile ducts, is one of the most
aggressive human malignancies. Gemcitabine and fluoropyrimi-
dine constitute the backbone of palliative chemotherapy (Hezel
and Zhu, 2008). 5-Fluorouracil (5-FU) displays clinical activity,
both alone and in combination with platinum-based agents, in
single arm phase II studies (Ducreux et al, 1998; Choi et al, 2000).
Oral fluoropyrimidine derivatives, including capecitabine and
uracil-tegafur (UFT), have been shown to be active as single
agents, as well as in conjunction with cisplatin (Kim et al, 2003;
Ikeda et al, 2005; Park et al, 2005).
S-1, an oral prodrug of 5-FU composed of tegafur, 5-chloro-2,
4-dihydroxypyridine (CDHP; gimestat), and potassium oxonate
(otastat), shows clinical efficacy in patients diagnosed with various
solid tumours, including biliary tract cancers (Park et al, 2009;
Sasaki et al, 2009). Combinations of S-1 and cisplatin have also
yielded modest response rates and tolerable toxicity profiles (Kim
et al, 2008b; Kang et al, 2010).
The pharmacokinetic and toxicity profiles of S-1 differ with
ethnicity (Hirata et al, 1999; Hoff et al, 2003; Chu et al, 2004). The
principal dose-limiting toxicities are diarrhoea in Caucasian and
myelosuppression in Asian patients (Hirata et al, 1999; Cohen
et al, 2002). These differences may be attributable to genetic
variations in CYP2A6 encoding a cytochrome P450 enzyme that
has a major role in the biotransformation of tegafur to 5-FU (Ikeda
et al, 2000). One clinical study demonstrated an association of the
CYP2A6*4 allele with exposure to 5-FU in non-small-cell lung
cancer patients receiving S-1, while another study suggested that
exposure to CDHP, which affects the metabolism of 5-FU, is the
key determinant of variability in 5-FU efficacy following S-1
administration (Fujita et al, 2008; Kaida et al, 2008).
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sThe primary objective of the present study was to evaluate
the efficacy and safety of S-1 in combination with oxaliplatin
chemotherapy in patients with metastatic BTC and objective
response rate was the primary endpoint. The secondary objective
was to evaluate the relationships between pharmacokinetics,
clinical activity and tolerability of S-1-based chemotherapy and
CYP2A6 genotypes.
PATIENTS AND METHODS
Eligibility criteria
Patients with histologically confirmed recurrent or metastatic
cancer of the biliary tract were eligible, provided that they met the
following criteria, including at least one unidimensionally
measurable lesion according to the Response Evaluation Criteria
in Solid Tumours (RECIST) guidelines Version 1.0, age between 18
and 70 years, Eastern Cooperative Oncology Group (ECOG)
performance status of 0–2, adequate haematological (haemoglobin
X9.0gdl
 1, absolute neutrophil count (ANC) X1.5 10
9l
 1, and
platelet count X100 10
9l
 1), hepatic (total bilirubin p1.5mgdl
 1,
serum transaminase p3 upper normal limit or p5 upper normal
limit in cases of hepatic metastases), and renal (serum creatinine
p1.5mgdl
 1) functions, no history of radiation therapy or
chemotherapy, including S-1 or oxaliplatin treatment within 6
months, and no history of gastrointestinal operations, including
gastrectomy or pancreaticoduodenectomy. Patients were excluded if
they had central nervous system metastasis, gastrointestinal obstruc-
tion, bleeding or sensory neuropathy greater than grade 2, according
t ot h eN a t i o n a lC a n c e rI n s t i t u t eo fC o m m o nT o x i c i t yC r i t e r i a
(NCI CTC) Version 3.0. Creatinine clearance was calculated using
the Cockcroft–Gault equation (Cockcroft and Gault, 1976). The
protocol was approved by the institutional ethics committee, and all
patients provided written informed consent before enrollment. This
study was conducted using the Good Clinical Practice guidelines,
in accordance with the Declaration of Helsinki and its amendments.
Study design and treatment
This was a single centre phase II study performed to evaluate the
efficacy and safety of the S-1 and oxaliplatin combination therapy.
S-1 was administered orally at a dose of 40mgm
 2 twice daily for
14 days, followed by a 7-day rest period. S-1 doses were calculated
in milligrams per square metre of body surface area, and rounded
down to the nearest 5 or 10mg. For pharmacokinetic analysis,
S-1 was given only once on day 1 of cycle 1. Beginning on day 2,
S-1 was administered twice daily. Oxaliplatin was administered
intravenously at 130mgm
 2 for 2h on day 2 of cycle 1, and day 1
of cycle 2 and subsequent cycles. Treatment was repeated every
21 days, and continued for a maximum of 9 cycles in the absence
of progressive disease, development of unacceptable toxicity, or
patient refusal.
Doses of S-1 and oxaliplatin were reduced based on the extent of
haematologic and non-hematologic toxicities evaluated before
each treatment cycle, according to NCI CTC toxicity scale Version
3.0. At the first occurrence of grade 3 thrombocytopenia or grade 4
neutropenia lasting o5 days, S-1 treatment was interrupted, but
was resumed at the same dose after resolution to grade 1 or better.
At the second or third occurrence of the same haematologic
toxicity with similar severity, treatment was interrupted, followed
by 25 or 50% dose reduction of S-1 and oxaliplatin (to 100 and
85mgm
 2, respectively) in subsequent cycles. If the haemato-
logic toxicity recurred with similar severity after adequate dose
reduction, treatment was discontinued. In cases of grade 3 or 4
non-hematologic toxicity, treatment was interrupted, followed by a
25 or 50% dose reduction, respectively. The oxaliplatin dose was
modified in cases where patients developed grade 2 neurosensory
toxicity. Treatment was interrupted until toxicity resolved to grade
1 or better, with reduction of the oxaliplatin dose to 100mgm
 2 in
subsequent cycles. In patients experiencing a second occurrence of
grade 2 neurosensory toxicity, treatment was interrupted, and the
oxaliplatin dose reduced to 85mgm
 2. Treatment was discon-
tinued if patients experienced recurrence of grade 2 neurosensory
toxicity after two oxaliplatin dose reductions, if oxaliplatin therapy
was delayed for 42 weeks because of toxicity, or if patients
developed grade 3 or higher neurosensory toxicity.
Efficacy and safety assessments
All patients who received at least one cycle of treatment were
subjected to efficacy and safety assessments. Response rate, the
primary endpoint, was evaluated according to the Response
Evaluation Criteria in Solid Tumours (RECIST) Version 1.0
(Therasse et al, 2000). Evaluation of tumours was performed every
two cycles. Chemotherapy was discontinued in cases of disease
progression, unacceptable toxicity or withdrawal of consent.
Adverse drug reactions were graded according to National Cancer
Institute Common Toxicity Criteria Version 3.0.
Pharmacokinetic assay
Blood samples (about 10ml) were collected in heparinised tubes at
0.5, 1, 2, 4, 8, 12, and 24h after the first single dosage of S-1
administered during cycle 1. Tubes were centrifuged (3500r.p.m.,
8min, 41C), and plasma immediately separated and transferred as
three aliquots into storage cryotubes, which were frozen at  801C
until analysis. Plasma concentrations of all compounds were
determined using liquid chromatographic–tandem mass spectro-
metry. Tegafur, FU, and CDHP were analysed on the API 3000
LC/MS/MS system (MDS Sciex, Concord, Ontario, Canada).
Plasma concentration data were used to calculate pharmacokinetic
parameters, including area under the curve from 0 to 24h
(AUC0 24h) and maximum concentration (Cmax), by the linear
trapezoid method using WinNonlin (Professional Network Version
5.2; Pharsight Corporation, Mountain View, CA, USA).
CYP2A6 genotyping assay
Genomic DNA was extracted from whole blood using a specific
DNA preparation kit (QIAamp Blood Mini Kit; Qiagen, Valencia,
CA, USA), according to the manufacturer’s instructions. Geno-
types of CYP2A6*1, *7, *9 and *10 allelic variants were determined
using the multiplex minisequencing (SNaPshot, ABI PRISM
SNaPshot Multiplex Kit; Applied Biosystems, Foster City, CA,
USA) method. Briefly, the full-length CYP2A6 gene was amplified
using a pair of primers, specifically, 50-CTCTCCCCTGGAACCCC
CAG-30 and 50-GCACTTATGTTTTGTGAGACATCAGAGACAA-30.
PCR was performed on a 9700 thermal cycler (PE Applied
Biosystems, Foster city, CA, USA) under the following conditions:
initial denaturation at 941C for 1min, followed by 30 cycles of 981C
for 20s, 641C for 30s, 721C for 3min 30s, and a final elongation
step at 721C for 10min. The 7.5kb PCR product was used as a
template for the SNaPshot reaction, which contained the following
sequencing primers: CYP2A6-48T4G( * 9 ) ,5 0-GGCTGGGGTGG
TTTGCCTTT-30; CYP2A6 6600G4T (*10), 50-GGAAGCTCA
TGGTGTAGTTT-30; and CYP2A6 6558T4G (*7), 50-CTCCCAGTC
ACCTAAGGACA-30. Genotype analyses were performed with
GeneMapper (Version 3.7) software (Applied Biosystems). For
genotyping the CYP2A6 deletion allele (*4), allele-specific ampli-
fication and restriction fragment length polymorphism analysis
were performed, as described previously (Nakajima et al, 2001).
Statistical analyses
Standard descriptive and analytical methods were used to describe
the patient population and their baseline characteristics. This trial
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swas designed using Fleming’s single-stage Phase II procedure to
test the null hypothesis that the true objective response rate was
o15%, with a sample size sufficient to reject it when the true
objective response rate was 435% with an 80% power and using a
level of a¼5% (one-sided test), and required a sample size of
44 patients (Machin et al, 1997; Kim et al, 2008b). We assumed a
dropout rate of 10%, making the required number of patients 49.
To analyse the effects of CYP2A6 genotypes, the pharmaco-
kinetic parameters of S-1 were log-transformed and compared using
mixed model analysis of variance (ANOVA). To evaluate CYP2A6
genotype-drug interactions, the differences in log-transformed mean
values between wild type (*1/*1) and variants (single or double)
were calculated, and both point estimates and 90% confidence
interval (CI) back-transformed to obtain geometric mean ratios,
along with CI values for the ratios. Progression-free survival (PFS)
was calculated from the commencement of chemotherapy to date of
disease progression or death from any cause, and overall survival
(OS) calculated from the start of chemotherapy to date of death
from any cause. Survival analyses were performed using the
Kaplan–Meier method with the log-rank test. Data analyses were
performed using the Statistical Software Package for Social Sciences
(SPSS version 14.0; Chicago, IL, USA).
RESULTS
Patient characteristics
From September 2006 to January 2008, we enrolled a total of
49 patients with histologically confirmed recurrent or metastatic
adenocarcinoma of the biliary tract (Table 1). No patient had
previously received radiation therapy or chemotherapy, including
S-1 or oxaliplatin. Median patient age was 52 years (range, 23–68
years), and 31 patients (63%) were male. Most patients
(94%) showed good performance status with ECOG scale values of
0–1. All patients had good renal function, and mean creatinine
clearance was 97.40mlmin
 1 (range, 57.13–198.0mlmin
 1).
A total of 30 patients (61%) were diagnosed with intrahepatic
cholangiocarcinoma, and 10 (20%) with gallbladder cancer. In all,
40 patients (82%) had metastatic abdominal lymphadenopathy,
with the liver being the most common metastatic organ (67%).
Efficacy
Among the 49 study patients, 45 were evaluated for response. The
remaining four subjects were lost to follow-up and hence were not
assessable. Partial response was observed in 24.5% (12 out of 49)
and stable disease in 34.7% (17 out of 49) of patients. The overall
response rate in the intention-to-treat population was 24.5%
(95% (CI), 12.5–36.5%; Table 2). Patients with gallbladder cancer
tended to show a higher response rate than those with intra- or
extra-hepatic cholangiocarcinoma, but the difference was not
statistically significant. At a median follow-up duration of
20 months (range, 9.4–25.6 months), median PFS and OS for all
patients were 3.7 months (95% CI: 1.7–5.7 months) and 8.7
months (95% CI: 4.8–12.6 months), respectively (Figure 1). We
observed no significant survival differences with respect to tumour
location (data not shown).
Drug exposure and safety
The 49 patients underwent a total of 216 treatment cycles (median,
4 cycles), 212 of which were assessable for toxicity. The frequencies
of haematological and non-haematological toxicities are sum-
marised in Table 3. The most common (45%) grade 3 out of 4
haematological toxicity was neutropenia with an incidence of 12%
(6 out of 49). However, no febrile neutropenia was observed. The
most common non-hematological grade 3 out of 4 toxicity was
anorexia (7 out of 49, 14%), followed by nausea (6 out of 49, 12%),
vomiting (5 out of 49, 10%), asthenia (2 out of 49, 4%), stomatitis
(2 out of 49, 4%), and diarrhoea (2 out of 49, 4%).
A total of 54 treatment cycles (26%, 54 out of 207 cycles) were
delayed in 24 patients. Chemotherapy doses were reduced for 65
out of 207 cycles (31%) in 26 patients. The median dose intensities
were 315.1mgm
 2 per week (range, 106.4–373.3mgm
 2 per
week) for S-1 and 39.4mgm
 2 per week (range, 24.2–43.3mgm
 2
per week) for oxaliplatin, with relative dose intensities of 84.4 and
91.1%, respectively.
Relationships among pharmacokinetic parameters, clinical
efficacy, toxicity of S-1, and CYP2A6 genotypes
CYP2A6 genotypes were analysed in all 49 patients, and full
pharmacokinetic data were obtained for 48 of the patients. Wild-
type homozygotes (CYP2A6*1/*1) were detected in 14 patients, and
Table 1 Patient characteristics (n¼49)
Characteristic No. of patients (%)
Median age, year (range) 52 (23–68)
Gender
Male 31 (63.3)
Female 18 (36.7)
ECOG performance status
0 25 (51.0)
1 23 (46.9)
2 1 (2.1)
Location of primary tumour
Gallbladder 10 (20.4)
Intrahepatic bile duct 30 (61.2)
Extrahepatic bile duct 9 (18.4)
Tumour differentiation
Well differentiated 5 (10.2)
Moderately differentiated 31 (63.3)
Poorly differentiated 10 (20.4)
Unknown 3 (6.1)
Disease status
Metastatic 32 (65.3)
Recurrent 17 (34.7)
Metastatic sites
Liver 33 (67.3)
Lung 12 (24.5)
Cervical node 2 (4.1)
Abdominal node 40 (81.9)
Peritoneum 19 (38.8)
Bone 2 (4.2)
Others 4 (8.2)
No. of metastatic organs
1 14 (28.6)
2 18 (36.7)
3 11 (22.4)
43 6 (12.2)
CA 19-9
Elevated 35 (71.4)
Normal 14 (28.6)
CYP2A6 genotype
a
1 homozygote
a 13 (27.1)
Single variant 28 (58.3)
Double variant 7 (14.6)
aCYP2A6 genotypes were performed in 48 patients.
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ssingle and double variants in 28 and 7 patients, respectively. The
allele frequencies of CYP2A6*4, *7, *9, and *10 were 10.2, 8.2, 19.4,
and 4.1%, respectively. These values did not deviate significantly
from the Hardy–Weinberg equilibrium.
In 48 patients, the 5-FU level reached peak plasma concen-
trations (Cmax) about 4h after administration of S-1. The
pharmacokinetic parameters are presented in Table 4. Plasma
concentrations of 5-FU tended to be higher in the CYP2A6 *1
homozygotes than patients with variant gene types (Figure 2).
Specifically, Cmax, 5 FU and AUC0 24h, 5 FU for CYP2A6 variant
types were 70% (90% CI: 55–88%) and 74% (90% CI: 56–98%)
those for *1 homozygotes (Table 4). On the other hand, FT plasma
concentrations were lower in the CYP2A6 *1 homozygotes,
compared with those in patients with genetic variations (Figure 2);
The Cmax,FT and AUC0 24h,FT values for CYP2A6 *1 homozygotes
were 17% (90% CI: 2–33%) and 37% (90% CI: 19–58%) higher
than those with variant genes (Table 4). CDHP plasma concentra-
tions were similar in both groups.
The ratio between exposure to 5-FU and FT (AUC0 24h of 5-FU/
AUC0 24h of FT) was 0.0710±0.0433 in the wild-type group
and 0.0331±0.0160 in patients with single or double variants
(Table 4, Figure 3), yielding a 1.85-fold higher metabolic ratio
(90% CI: 1.37–2.49) in the wild-type group. However, comparison
of the frequencies of diarrhoea and neutropenia between wild type
and variants revealed that the CYP2A6 *1/*1 genotype was not
significantly associated with any grade of diarrhoea (wild
type, 5 out of 13, vs variant type, 7 out of 35; P¼0.0740) or
neutropenia (wild type, 4 out of 13, vs variant type, 7 out of 35;
P¼0.396). In addition, exposure to 5-FU (AUC0 24h, 5 FU) was not
significantly correlated with severity of diarrhoea or neutropenia
(Figure 4).
DISCUSSION
This study evaluated the efficacy and safety of S-1 and oxaliplatin
in Korean patients with metastatic biliary tract carcinoma. The
response rate was 24.5%, and median PFS and OS were 3.7 and 8.7
months, respectively, similar to results obtained from trials of S-1
combinations with cisplatin and oxaliplatin (Kim et al, 2008b; Oh
et al, 2008). The frequencies of diarrhoea (4%) and neutropenia
(14%) exceeding grade 3 were comparable with those of other
studies, which used similar dosages of S-1 and oxaliplatin (Yamada
et al, 2008; Zang et al, 2009).
Recently, survival gain in biliary tract cancers with gemcitabine-
based chemotherapy was reported. Moreover, a combination of
gemcitabine and cisplatin displayed benefits over gemcitabine
monotherapy in a randomised, phase III trial (Valle et al, 2010).
A small-scale randomised phase II trial showed that survival rates
with gemcitabine and oxaliplatin surpassed those with fluorouracil
and folinic acid in unresectable gall bladder cancer (Sharma et al,
2010). On the other hand, several phase II trials have supported the
utility of 5-FU-based containing regimens for biliary tract cancers
(Eckel and Schmid, 2007). Although gemcitabine-based chemo-
therapy may be the preferred treatment based on recent phase III
Table 2 Treatment response (intention-to-treat analysis, n¼49)
Response
Gallbladder
cancer (n¼10)
Intrahepatic
CCC (n¼30)
Extrahepatic
CCC (n¼9)
All patients
(n¼49)
CR — — — —
PR 4 (40.0%) 7 (23.3%) 1 (11.1%) 12 (24.5%)
SD 4 (40.0%) 9 (30.0%) 4 (44.4%) 17 (34.7%)
PD — 12 (40.0%) 4 (44.4%) 16 (32.7%)
NE
a 2 (20.0%) 2 (6.7%) — 4 (8.2%)
Abbreviations: CR¼complete response; PR¼partial response; SD¼stable disease;
PD¼progressive disease; NE¼not evaluable; CCC¼cholangiocellular carcinoma.
aFour patients were lost to follow-up.
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Figure 1 Kaplan–Meier curves of progression-free survival (PFS) and
overall survival (OS) for all 49 patients. Median PFS and OS were 3.7
months (95% CI: 1.7–5.7 months) and 8.7 months (95% CI: 4.8–12.6
months).
Table 3 Common (45%) haematological and non-haematological toxicities (intention-to-treat analysis)
Toxicity per cycle (N¼212) Toxicity per patient (N¼49)
Adverse events Grade 1 Grade 2 Grade 3 Grade 4 Grade 1 Grade 2 Grade 3 Grade 4
Anaemia 57 14 2 4
a 28 7 1 2
a
Leukopenia 18 18 — — 9 9 — —
Neutropenia 12 14 14 — 6 7 6 —
Thrombocytopenia 51 22 6 — 27 11 3 —
Asthenia 43 49 10 — 19 21 2 —
Anorexia 57 12 14 — 29 6 7 —
Nausea 55 14 12 — 25 7 6 —
Vomiting 22 8 10 — 11 4 5 —
Stomatitis 39 2 2 — 20 2 2 —
Diarrhoea 33 6 4 — 15 3 2 —
Constipation 49 6 — — 21 4 — —
Neuropathy 88 2 — — 41 2 — —
Hand-foot syndrome 18 2 — — 9 1 — —
aTwo patients experienced tumour bleeding.
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strials, it is not evident whether gemcitabine surpasses fluoropyri-
midine in terms of efficacy (Kim et al, 2008a). Combination
chemotherapy consisting of gemcitabine, 5-FU derivatives
and platinum analogue regimens led to response rates between
20 and 30% and median survival of 8–12 months (Verslype et al,
2008).
The recorded overall response of 24.5% meant that our
study did not meet its primary endpoint response rate of 35%.
However, some biologic features of biliary tract cancers should be
considered. First, response rates and survival differ significantly
according to the primary site of the tumour, and intrahepatic
cholangiocarcinoma has the worst prognosis (Park et al, 2009).
The proportion of intrahepatic cholangiocarcinoma was substan-
tially higher than expected (61%), which may have influenced
the overall response rate. Second, many studies have used tumour
control rate (defined as stable disease, complete or partial
response) to assess efficacy owing to the aggressive nature of
advanced biliary tract cancer. We recorded a tumour control rate
of 59.2%, which is comparable with data from previous studies
with S-1 and cisplatin (Kim et al, 2008b). Third, we recently
showed that gemcitabine was better than S-1 as a doublet partner
for platinum agents in advanced biliary cancers (Kang et al, 2010).
However, gemcitabine was associated with higher toxicities,
especially neutropenia and thrombocytopenia. As fluoropyrimi-
dine-based chemotherapy induces lower haematological toxicities
and decreased tendency of biliary tract cancer-related infections,
including cholangitis and liver abscess, S-1 use may be favored in a
subset of patients (Kim et al, 2008a). Moreover, S-1 offers the
convenience of oral administration, in contrast to the weekly
intravenous administration of gemcitabine. Therefore, well-de-
signed randomised phase III trials are required to compare
fluoropyrimidine plus platinum combination with gemcitabine
plus platinum combination chemotherapy in terms of efficacy
and safety.
Despite these advantages, S-1 pharmacokinetics is subject to
interindividual variability, which is explained by the pharmaco-
genetics of CYP2A6 (Goh et al, 2008). The variant genotypes of
CYP2A6 display decreased baseline enzyme activity, leading to
reduced 5-FU formation. We categorised pharmacokinetic para-
meters as ‘wild type’ (*1/*1) and ‘variant type’ (single and double
variant) genotypes, consistent with pharmacogenetic studies
on nicotine, another substrate of CYP2A6 (Schoedel et al, 2004;
Nakajima et al, 2006; Mwenifumbo et al, 2007). On comparing the
Table 4 Pharmacokinetic parameters of 5-FU, FT, and CDHP according to CYP2A6 genotype
CYP2A6 *1
homozygote
Single-variant
of CYP2A6
Double-variant
of CYP2A6
Point estimate ratio
(90% confidence interval)
a
5-FU
Cmax (ngml
 1) 218.1±95.88 144.5±43.35 138.1±70.03 0.70 (0.55–0.88)
AUC0–24h(hngml
 1) 1295±590.4 875.5±303.0 1154±1262 0.74 (0.56–0.98)
FT
Cmax (ngml
 1) 2095±497.0 2398±559.1 2691±948.2 1.17 (1.02–1.33)
AUC0–24h(hngml
 1) 20770±6831 27060±5101 32380±14650 1.37 (1.19–1.58)
CDHP
Cmax (ngml
 1) 28.23±10.44 30.32±15.62 39.73±24.55 1.06 (0.80–1.40)
AUC0–24h(hngml
 1) 203.4±46.83 213.5±125.6 208.1±132.4 0.93 (0.72–1.20)
5-FU/FT
Cmax 0.1083±0.0494 0.0618±0.0195 0.0526±0.0205 1.67 (1.31–2.13)
AUC0–24h 0.0710±0.0433 0.0327±0.0100 0.0348±0.0315 1.85 (1.37–2.49)
Abbreviations: FT¼tegafur; Cmax¼maximum plasma concentration; AUC0–24h¼area under the plasma concentration-time curve from time 0–24h; 5-FU/FT¼ratio between
the pharmacokinetic parameters of 5-FU and FT.
aPoint estimate ratio between single or double variant and *1 homozygote. Individual pharmacokinetic parameters are
expressed as means±s.d.
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Figure 2 Mean concentration–time curves of 5-FU (A), FT (tegafur, B),
and CDHP (C) in 48 patients treated with S-1 and oxaliplatin.
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genotype, this ratio was 1.85-fold greater in the*1/*1 group than
the variant-type group. A previous study reported that non-small
cell lung cancer patients with CYP2A6*4 alleles, which complete
lack relevant enzymatic activity, show significantly lower plasma
concentrations of 5-FU (Kaida et al, 2008). In addition to
CYP2A6*4 alleles, CYP2A6*7, *9, and *10 displayed decreased
enzyme activity. Our present observations have expanded the
application of CYP2A6 genotyping by including various alleles in
the interpretation of S-1 pharmacokinetics.
Despite differences in exposure, the CYP2A6 genotype was not
significantly associated with clinical efficacy or incidence of toxicity,
suggesting that the pharmacokinetic-pharmacodynamic relationships
of 5-FU are complicated. Studies using various schedules and
formulations of 5-FU have reported a correlation between exposure
to 5-FU and toxicity, particularly diarrhoea (Cohen et al, 2002; Chu
et al, 2004; Ajani et al, 2005; Gusella et al, 2006; Gamelin et al,2 0 0 8 ) .
Conversely, other studies have been unable to establish an association
between the AUC of 5-FU and toxicity after S-1 administration
(Hirata et al, 1999). This lack of association may also be attributed to
the other constituents of S-1. The action of oxonate, which inhibits
the orotate phosphoribosyl-transferase (OPRT) enzyme in intestinal
tissue and decreases the occurrence of diarrhoea, may be related to
interindividual differences (Shirasaka et al, 1993; Peters et al,2 0 0 3 ) .
The clinical efficacy of fluoropyrimidines, including S-1, is influenced
by thymidylate synthase, which may confound the association
between 5-FU exposure and clinical efficacy (Ichikawa et al,2 0 0 4 ) .
A recent investigation reported a correlation between the CYP2A6
genotype and efficacy of S-1-based chemotherapy in advanced gastric
cancer (Kong et al, 2009). However, pharmacokinetic data for
clarifying the exposure-effect relationship were not evaluated.
S-1 is mainly used in Korea and Japan, whereas capecitabine
is often used in Western countries. In a study on the efficacy
of capecitabine and oxaliplatin in advanced biliary tract cancers,
Nehls et al (2008) observed a tumour control rate of 77%, which
is higher than that obtained in our study. However, it must be
noted that patient characteristics between the two studies
differed, since we analysed more cases of intrahepatic cholangio-
carcinoma, which has the worst prognosis among the biliary tract
cancers. An additional finding is that the recommended dose
of S-1 for Asians is higher than that for Caucasians (Hoff et al,
2003). This has been explained by the fact that Caucasians show
a higher frequency of wild-type CYP2A6 and suffer from
gastrointestinal toxicities. Another Korean group recently reported
adequate efficacy and safety with 50mgm
 2 S-1 twice a day in
combination with 130mgm
 2 oxaliplatin for colorectal cancer
(Kim et al, 2009).
In conclusion, the present results suggest that a combination
of S-1 and oxaliplatin is active and safe for patients with
advanced biliary tract cancer. At present, gemcitabine is favored
as the backbone for chemotherapy in biliary tract cancers, based
on efficacy studies. However, an oral 5-FU based regimen, such as
capecitabine or S-1, may be preferable in terms of convenience.
Large-scale studies are required to properly address this issue. Our
findings further indicate that differences in the CYP2A6 genotype
may affect individual pharmacokinetics of S-1, but do not have a
significant impact on clinical efficacy or toxicity.
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